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When injured by crushing, the repair of the slow-twitch soleus rat muscle, unlike the fast-twitch EDL, is associated with ﬁbrosis.
As TGFβ1, whose activity can be controlled by glycosaminoglycans (GAG), plays a major role in ﬁbrosis, we hypothesized that
levels of TGFβ1 and GAG contents could account for this diﬀerential quality of regeneration. Here we show that the regeneration
of the soleus was accompanied by elevated and more sustained TGFβ1 level than in the EDL. Neutralization of TGFβ1e ﬀects
by antibodies to TGFβ1o ri t sr e c e p t o rT G F β-R1 improved muscle repair, especially of the soleus muscle, increased in vitro
growth of myoblasts, and accelerated their diﬀerentiation. These processes were accompanied by alterations of GAG contents.
These results indicate that the control of TGFβ1 activity is important to improve regeneration of injured muscle and accelerate
myoblast diﬀerentiation, in part through changes in GAG composition of muscle cell environment.
Copyright © 2009 M. Zimowska et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Skeletalmusclehasagreatabilitytoregenerateinresponseto
injuryordisease[1,2].Theregenerationprocessisattributed
to mononucleated cells found in adult skeletal muscles
located between the basal lamina and the plasmalemma of
muscle ﬁbers. Recent work has shown that these so-called
satellite cells are a heterogeneous population comprising
stem cells and committed progenitor cells (reviewed in [3–
6]). Stimulated by damage to the muscle ﬁber, satellite cells
are activated to enter the cell cycle; they fuse either together
or with myoﬁbers in order to restore muscle architecture and
function with more or less eﬃciency [2, 7, 8].
Most muscles are a mosaic of fast and slow ﬁbers [9, 10].
Due to their composition, the slow-twitch muscle soleus and
the fast-twitch muscle Extensor digitorum longus (EDLs) are
widelyusedasmodelsbecausetheyarecomposedinmajority
or almost totally of slow or fast type ﬁbers reciprocally,
depending on animal species. Studies of the regenerative
response of these two muscles to injury, induced, for
example, by a microlesion [11] or an anesthetic injection
[12, 13], have found diﬀerences in the way these two types
of muscle get repaired. This is particularly true in a whole
musclecrushmodelinratwherethesoleusmuscleundergoes
ﬁbrosis in contrast to the EDL muscle that regenerates
correctly [14].
Intrinsic properties of satellite cells involved in muscle
repair might contribute to the diﬀerential repair processes
of fast and slow skeletal muscles in rats. Several studies,
including our previous works [13, 15–17], have reported
that myoblasts isolated from fast or slow muscles and grown
in vitro display some diﬀerential growth and diﬀerentiation
properties. The diﬀerences of myoblasts from fast and slow
muscles are maintained independently of the phenotypic
transition of muscle ﬁbers induced by an adequate chronic
electrical stimulation.
Cytokine and growth factor activities could be proposed
to account for the diﬀerential features of regenerating slow2 International Journal of Cell Biology
and fast skeletal muscles. Among growth factors known
to modulate the regeneration process, those belonging to
the transforming growth factor beta (TGFβ)f a m i l ys e e m
to play speciﬁc roles in muscle development and after
injury [18]. Works in the 1980s and after have shown
that TGFβ negatively regulates muscle cell proliferation
and diﬀerentiation [19]. This cytokine can also inﬂuence
muscle ﬁber type patterning in regenerating muscles after
injury [20]. In addition, TGFβ family members are well
known to play a major role in ﬁbrosis development and
scar formation since they stimulate extracellular matrix
(ECM) production, modulate the expression of ECM-
degrading enzymes and proteinase inhibitors [21, 22]. In
the C2C12 myoblast cell line, TGFβ1 can stimulate its
own synthesis in an autocrine manner and triggers cells
to diﬀerentiate into myoﬁbroblasts in injured muscle [23].
TGFβ1 is also connected with ﬁbrosis during congenital
muscular dystrophy and Duchenne’s dystrophy [24–26].
Thus, this cytokine initiates a ﬁbrotic cascade in skeletal
muscles that needs to be hindered [24, 27, 28] and reduction
of TGFβ1 expression or activity would appear promising
for improving muscle repair, as suggested by earlier studies
[25, 29].
Diﬀerences in matrix component environment could
also be evoked to account for muscle regeneration abil-
ity in particular in the case of the whole muscle crush
model. Muscle environment has a profound eﬀect on the
regenerative capacity of resident muscle precursor cells and
implanted cells [30, 31]. Among ECM components and
membrane-associated components that contribute to cellu-
lar environment, proteoglycans (PGs) have been implicated
in numerous physiological and pathological processes such
as enzyme regulation, cellular adhesion, growth, migration,
and diﬀerentiation [32, 33]. The eﬀect of PG is mainly due
to the glycosaminoglycan (GAG) moiety of these molecules,
principally the heparan sulphate (HS) and the dermatan
sulphate/chondroitine sulphate (CS/DS) (see [34, 35]f o r
reviews). In particular, HS plays a prominent role in
skeletal muscle development and physiology [36]. We have
demonstrated that HS is increased during diﬀerentiating
myoblast [37]. ECM composes a reservoir for growth factors
including TGFβ [38, 39]. Among PGs that belong to muscle
environment, some of them such as decorin, biglycan, and
betaglycan have been implicated in the regulation of TGFβ
bioavailability in skeletal muscle, modulating myogenesis
progression [26, 40]. It is generally believed that TGFβ
signaling is initiated by its binding to the proteoglycan
betaglycan and then to the TGFβ receptors type II and
I heterodimer from where a signal is transduced [41–43].
Although TGFβ is known to bind to betaglycan core protein
[44], modiﬁcations in GAG moiety of this PG modulate
TGFβ binding to TGFβ receptors and modulate downstream
signalling [45]. Thus, the acquaintance with GAG content
and composition after tissue injury may be of particular
importance in the understanding of processes involved in
tissue repair. The balance between secreted cytokines such
as TGFβ and GAG network may represent a homeostatic
mechanism aimed at controlling the skeletal muscle repair
process.
The main hypothesis presently explored was that TGFβ1
level could at least partially account for the diﬀerential
regeneration abilities of soleus and EDL muscles through
modulating myoblast diﬀerentiation and GAG cellular envi-
ronment. An impairment of TGFβ activity was achieved
using injection of anti-TGFβ1 or anti-TGFβ receptor I
(TβRI) antibodies into crushed soleus or EDL muscles in
vivo or by treating primary cultures of myoblasts isolated
from both muscles with these antibodies. The eﬀects of
these treatments were analyzed on muscle regeneration and
myoblast diﬀerentiation. Attention was also focused on
GAGsintheenvironmentofsatellitecellsandinregenerating
muscles. Taken together, results suggested that TGFβ1a n d
GAGs interplay in regulating muscle repair and myoblast
diﬀerentiation.
2.MaterialsandMethods
2.1. Materials. Dulbecco modiﬁed essential medium
(DMEM), foetal bovine serum (FBS), and horse serum
were from Gibco, Invitrogen Life technology. Primary and
secondary antibodies were from Santa Cruz Biotech. PVDF
membrane and immunoblotting detection reagents were
from Roche. Reagents for ELISA assay were from R&D, BD
Biosciences. Other reagents were purchased from Sigma.
2.2. Surgical Procedure and Regeneration Experiments. All
procedures involving animals were approved by the Ethics
Committee in the Care and use of Animals (192/2002). The
regeneration of soleus and EDL muscles was induced in
3-month-old male Wistar rats according to [14]. In brief,
rats were anaesthetized with an intraperitoneal injection of
ketamine (6mg/kg) and xylasine (60mg/kg) mixture and the
muscle was exposed. Tendons were kept in place but motor
nervewascutatthemusclesurface.Thenmusclewascrushed
from tendon to tendon with a Pean haemostatic forceps. The
muscle was then put back in its bed. After skin closure, ani-
mals were allowed to recover and were returned to their cage
with food and drink at libitum. This procedure ensured a
goodreproducibilityoftheregenerationprocessandinduced
an exhaustive myolysis of all ﬁbers thus validating further
biochemical analysis on injured muscles. Antibodies against
TGFβ1o rT G F β-receptor I (TβRI) were injected just after
crush (100μg per muscle in 50μL) into the muscles referred
to as treated muscles. At diﬀerent days after injury, animals
were euthanasized in CO2 and the regenerating muscles of
each animal were removed and weighed. Muscles were then
either directly used for biochemical investigations or freezed
in isopentane precooled in liquid nitrogen, then stored at
−80◦C pending histological or biochemical studies. Three
rats were used for each muscle type and the experiment was
repeated3times.Contralateralintactmuscleswerealsotaken
for comparison to injured muscles.
2.3. Histological Analysis of Regenerated Muscle. Transversal
cross-sections of control or treated soleus and EDL muscles
were cut (10μm thick) on a cryostat (Microm, Germany)International Journal of Cell Biology 3
and stained with the Gomori Trichrome technique for
histological examination.
2.4. Myoblast Primary Cultures. Satellite cells were dissoci-
ated with pronase from soleus or EDL muscles of 3 months
old Wistar male rats, as previously described [16]. Cells were
seeded (2000cells/cm2) on dishes coated with 0.1% gelatin
and grown continuously in DMEM containing 10% fetal
bovine serum and 10% horse serum in 5% CO2 at 37◦C.
At days 4, 6, 8, 10, 12, or 14 cellular growth was measured
by counting the cells after trypsinization medium was
collected and cells were homogenized for immunoblots or
for GAG measurements. Histological aspects of the cultures
were assessed by Hoﬀman contrast observations (Nikon
microscope). Some cultures were stained with the Giemsa-
May-Gr¨ unwald technique for myotube analysis and fusion
index determination. The size of myotubes was evaluated
by counting the number of nuclei found in each myotube.
The fusion index represents the percentage of nuclei found
in myotubes divided by the total number of nuclei in the
culture. These counts were performed on 10 representa-
tive microscopic ﬁelds of each plate belonging to several
cultures.
2.5.CellTreatments. Insomeexperiments,myoblastcultures
were treated either with anti-TGFβ1 or anti-TβRI antibod-
ies. According to preliminary experiments performed to
determine the optimum concentration and frequency of
treatmentwithantibodiestobeused,soleusorEDLmyoblast
cultures were treated at day 4 and then every 2 days along
with medium change with 1μg/mL anti-TGFβ1 antibody.
Either 1.5μg/mL or 1.0μg/mL of anti-TβRI was used on
soleus and EDL myoblasts, respectively.
2.6. Immunoblot Analysis. Experiments were performed for
control or treated regenerated muscles and cell cultures.
Regenerated muscle in vivo or cells grown in vitro were
lysed in ice-cold buﬀer containing 20mM Tris-HCl, 5mM
EGTA, 5mM EDTA, 150mM KCL, 1% Nonidet, 0.5%
sodium deoxycholate, 0.01% leupeptin, 0.5mM PMSF, and
10mM β- m e r c a p t o e t h a n o la tp H7 . 5 .A l lo p e r a t i o n sw e r e
performed on ice. Protein concentration was quantitatively
determined using the Bradford Biorad Protein assay. Twenty
μg of protein in Laemmli sample buﬀer were loaded onto a
sodium dodecyl sulfate 10% acrylamide gel, transferred to
PVDF membrane, and incubated with polyclonal antibodies
raised against TGFβ1o rT βRI or Fibronectin at ﬁnal
dilution 1 : 200 (overnight, 4◦C). The blots were then
incubated with peroxidase-conjugated antirabbit antibodies
(1 : 2000, 1.5 hours, room temperature). The loading of
gels was routinely controlled using anti-α-tubuline [46].
The immunoblots were visualized by chemiluminescence
and exposed to ﬁlm (Kodak). An image of the gel was
captured using the GelDoc2000 scanner and protein bands
were analyzed using Quantity One program (BIORAD)
and graphed using Excel. Each experiment was performed
3 times and the results were expressed in percentage as
mean ± SE.
2.7. ELISA Measurement of TGFβ1. Immunoassays were
performed with extracts from control soleus or EDL regen-
erating muscles. Muscles were homogenized in lysis buﬀer;
protein concentrations were determined using the Bradford
Biorad Assay. One hundred μL of samples containing 20μg
of total protein were assayed according to the manufacturer
procedure. Duplicate measurements for each standard and
samples were performed.
2.8. Sulphated GAG Measurement. Total sulphated GAGs
were measured as described in Barbosa et al. 2003 [47]. In
brief, homogenates from cellular layer or muscle fragments
were performed in phosphate buﬀer (K2HPO4,5 0m M ,p H
8.0). Cellular extracts were then treated with 50μg/mL pro-
teinase K in phosphate buﬀer at 56◦C overnight. Heating the
preparation 10 minutes at 90◦C then inactivating proteinase
K, at this step, the amount of DNA in aliquot samples was
determined by 4,6-diamino-2-phenylindole (DAPI) assay
using salmon sperm DNA as standard [48]. Digested tissues
were then treated with DNAse (Qiagen, France) used at
7.5units/100mg fresh weight overnight at 37◦Ci no r d e rt o
eliminate interfering DNA. These preparations were used for
sulphated GAG quantitation.
Total sulphated GAGs and HS GAG species were quan-
titated using the method based on dimethylmethylene blue
co-precipitation with GAGs according to [47]. HS was
quantitated after treatment of total GAG preparations with
chondro¨ ıtinase ABC (20mU/100μL, 2 hours, Sigma).
2.9. Statistical Analysis. Each experiment was repeated at
least three times. Data are expressed as mean ± standard
error (SE). Statistical signiﬁcance was determined using a
Student’s t-test (GraphPad Software, San Diego, Calif, USA).
3. Results
3.1. Diﬀerential Characteristics of Regenerating Soleus and
EDL Muscles after Crush. Histology of soleus and EDL
muscles in the course of crush-induced regeneration is
shown on Figure 1. After crush, a complete muscle ﬁber
myolysis occurs in both muscles, that is, almost achieved
at day 3 (Figure 1 Control pictures). At day 7, numerous
s m a llﬁ b e r sc a nb eo b s e rv e di nb o t hs o l e u sa n dE D Lm u s c l e s .
However, whereas the EDL muscle was regenerated correctly
and showed a well-structured muscle at days 14 and 64 after
crush, the soleus showed heterogeneous ﬁber size at day
14 after crush. Regeneration did not progress further and
ﬁbrosis, already obvious at day 14, remained at day 64. Both
types of muscles also diﬀered by muscle regulatory factor
(MRF) protein patterns. Indeed, MRFs were activated earlier
in regenerating EDL than in soleus muscle. In both muscles,
levels of MyoD and myogenin were successively increased.
However, in soleus muscle, MyoD peaked at days 5–7 and
myogenin at day 14, whereas in EDL muscles these MRFs
peaked earlier, MyoD being at its maximum at day 3 and
myogenin at day 7 (Figure 2).
Immunoblot analysis of TGFβ1 performed with extracts
prepared from regenerating muscles (Figure 3(a)) revealed4 International Journal of Cell Biology
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Figure 1: Histological aspects of regenerating soleus and EDL muscles. Transversal cryosections of intact muscles, control muscles, or muscles
that were injected with anti-TGFβ1 antibody were performed at the indicated days after crush. Sections (10μm) were stained with Gomori
Trichrome as described in the Materials and Methods Section. Bars: 50μm.
that in soleus muscle TGFβ1 increased at day 1 after crush
and remained at a high level up to 14 days. At day 64
after crush, TGFβ1 level was still slightly higher than in
intact muscle. In EDL regenerating muscle, TGFβ1a m o u n t
increased at day 1 then diminished to the control level
as early as day 7 after crush. Measurements of TGFβ1b y
ELISAtechniquecorrelatedwithimmunoblottingevaluation
at least for the ﬁrst 7 days after crush. (Figure 3(b)). The
amount of TGFβ1 protein in intact soleus muscle was
4.19pg ± 0.39. In this muscle, it increased 3 to 4 times at
days 1 and 3 after crush to reach more than 21pg per muscle
at day 3; then, it decreased at day 7, when it still remained
about twice higher than in control muscle. In the EDL intact
muscle, TGFβ1 protein amount measured by ELISA was
3.24pg ± 0.44. It increased to about 12pg/muscle at day 1,
then regularly decreased reaching the control level at day 7.
Thus, the pattern of TGFβ1 protein level whatever its
origin (inﬂammatory cells or muscle cells) is diﬀerent in
soleusandEDLregeneratingmuscles.Itremainedatahigher
level a much longer time in soleus than in EDL muscle.International Journal of Cell Biology 5
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Figure 2: Pattern of MyoD and myogenin proteins in regenerating EDL and Soleus muscles. Representative immunoblots of (a) MyoD and (b)
myogenin performed on extracts from regenerating soleus and EDL muscles at the indicated days after crush are shown. (c) Alphatubulin
was routinely used as control of loading. Band densities of membranes from 3 diﬀerent samples were scanned as described in Materials and
Methods and mean values ± SE are shown as OD arbitrary units.6 International Journal of Cell Biology
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Figure 3: TGFβ1 protein levels during soleus and EDL muscle regeneration. (a) Representative immunoblots of TGFβ1 performed on extracts
from control untreated soleus and EDL muscles taken at the indicated days after crush. Alphatubulin was used as control of loading. (b)
TGFβ1 protein amount measured by ELISA during the ﬁrst week after crush in untreated regenerating muscles (control). Levels of TGFβ1
areshownaspgpermusclefreshweight.InintactsoleusandEDLmuscles4.19pgpermuscleand3.24pgpermusclewerefound,respectively.
The data represent mean ± SE of 3 independent determinations each of them including 3 animals. All values found in regenerating muscles
were statistically diﬀerent from intact muscles (P<. 05) except for EDL day 7. (c) Representative Immunoblots of TGFβ1i ne x t r a c t sf r o m
muscles injected just after crush with anti-TGFβ1 antibody and taken at the indicated days after crush.
3.2. TGFβ1 Antibody Improves Skeletal Muscle Regeneration.
Anti-TGFβ1 antibodies wereinjected into theinjured muscle
after crush to further validate the hypothesis that sustained
TGFβ1 action would explain the presence of ﬁbrosis in
regenerating soleus. The presence of anti-TGFβ1i m p r o v e d
the structure of regenerating muscles (on Figure 1 see
“anti-TGFβ1” compared to “controls”). Muscle regeneration
improvement was especially remarkable in the case of soleus
muscle. The diameters of ﬁbers were larger and more
homogenousinsize.Treatmentofmusclesofbothtypeswith
anti-TGFβ1 antibody allowed the restoration of muscular
architecture similar to an intact muscle at day 64.
It was not possible to quantitate TGFβ1 by ELISA
technique in the anti-TGFβ1-treated muscles because of
the presence of antibodies in the extract that would interfere
with the test but immunoblot showed that the treatment of
soleus or EDL muscles with anti-TGFβ1 antibody reduced
the amount of TGFβ1 protein compared to untreatedInternational Journal of Cell Biology 7
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Figure 4: Eﬀect of anti-TGFβ1 on ﬁbronectin protein level during soleus and EDL muscle regeneration. Densitometric analysis of immunoblots
performed on extracts from control untreated or anti-TGFβ1 treated soleus and EDL muscles at the indicated days after crush. Level found
in the corresponding intact muscle was taken as reference (100%). Results are mean ± SE of 3 independent determinations each of them
including 3 animals. Representative immunoblots of ﬁbronectin from control and treated soleus and EDL muscles are also shown. α-tubulin
was used as control of loading.
regenerating muscles (Figure 3(c)). Interestingly, TGFβ1
protein level was diminished in the soleus muscle as soon as
day 7 after crush in treated muscles.
The reduction of TGFβ1 protein level in the presence of
anti-TGFβ1correlatedwithimprovementofthemusclemor-
phology shown by histology (Figure 1). To further evaluate
the impact of TGFβ1 impairment on ﬁbrosis in the muscle
tissue, ﬁbronectin protein expression was examined in both
muscle types in the course of regeneration. This protein of
the extracellular matrix is indeed widely used as a marker
of tissue ﬁbrosis, in particular in skeletal muscle where it
is part of endomysium and perimysium [49]. The level of
ﬁbronectininuntreatedsoleusregeneratingmuscle(control)
at day 1 after crush was about 2-3 times higher than in an
intact muscle taken as a reference (100%) (Figure 4). Then,
ﬁbronectin protein level further increased in regenerating
soleus muscle, reaching its highest level at day 14 (644%)
after crush. At this time, ﬁbrosis was clearly visible on
histological pictures. In EDL muscles which spontaneously
regeneratecorrectlywithoutanytreatmentafterinjuryinthis
model, ﬁbronectin protein increased about 3 times at day
1 after crush but decreased to almost intact level at day 15
aftercrush.TreatmentofEDLregeneratingmusclewithanti-
TGFβ1 antibody slightly decreased the level of ﬁbronectin
protein. In contrast, in soleus muscle anti-TGFβ1 antibody
highly decreased the level of ﬁbronectin protein especially
at day 14 after crush. These results illustrated a beneﬁcial
role of anti-TGFβ1 to reduce ﬁbrosis during soleus muscle
regeneration.
3.3.PropertiesofMyoblastsIsolatedfromSoleusandEDLMus-
cles. Immunohistological studies have shown that TGFβ1
was found around muscle ﬁbers in intact muscles, some
cells at the periphery of ﬁbers being highly labelled. In
regenerating muscles, the antibody against TGFβ1 decorated
small cellular structures, presumably activated satellite cells
or small myotubes (not shown). This suggested that the
TGFβ1 found in regenerating muscles, especially in soleus
type muscle, might be attributable not only to ﬁbroblasts or
inﬁltrating inﬂammatory cells [50] but also to resident myo-
genic cells. Therefore, we investigated whether diﬀerences
between fast and slow type muscles, especially as concerns
TGFβ1 protein level, could result, at least in part, from
intrinsic properties of myoblast cells.
Patterns of proliferation and diﬀerentiation of myoblasts
isolated from soleus and EDL muscles were established at
ﬁrst. Morphological aspects of these cultures are shown
on Figure 5. Under our culture conditions, where a high
concentrationofserumwaspermanentlyused(10%FBSand
10% horse serum), the number of cells began to increase
after the 4th day following plating. It increased continuously
u pt od a y1 0i ns o l e u s( Figure 6(a)) and EDL (Figure 6(c))
cell cultures when it reached a plateau. However, this plateau
in soleus cultures at day 10 was about 50% higher than in
EDLcultures.Spontaneousdiﬀerentiationinculturesdidnot
begin prior to the 6th day after plating. In soleus myoblast
control cultures (Figures 6(a) and 6(b)), the ﬁrst myotubes
appeared at day 6, thus earlier than in the EDL myoblast
cultures (Figures 6(c) and 6(d)), and the myotubes formed8 International Journal of Cell Biology
were bigger than in the EDL cells. For instance, at day 10,
myotubescontainingmorethan20nucleiwereseeninsoleus
cell cultures whereas the biggest myotubes seen in EDL cell
cultures contained only up to 14 nuclei. But ﬁnally, at day 14
after plating, fusion index reached about 55% in both types
of myoblast cultures. This showed that soleus myoblasts
diﬀerentiated more precociously than EDL myoblasts.
3.4. Impairment of TGFβ1 Activity by Anti-TGFβ1o rA n t i -
TGFβReceptorI(TβRI)AntibodiesIncreasedProliferationand
AcceleratedMyoblastFusion. Treatmentsofculturesfromday
4 with anti-TGFβ resulted in an increased myoblast growth
and accelerated myotube formation in myoblasts isolated
from both soleus (Figures 6(a) and 6(b)) or EDL muscles
(Figures 6(c) and 6(d)). The stimulation of proliferation
were more striking in the case of soleus myoblast cultures
especiallybetweendays6and10,butﬁnallythetotalnumber
of cells was not increased at day 14 compared to untreated
controls. In EDL cell cultures, the rate of proliferation was
highly increased after day 8 (4 days of treatment), and
ﬁnally at day 14, there were about 60% more cells in treated
cultures. This suggested that TGFβ1 behaves as an inhibitor
of myoblast growth and that impairment of its activity
increases cell proliferation.
Compared to control, anti-TGFβ1 antibody also highly
accelerated myoblast fusion as shown on Figure 5. The index
of fusion (Figure 6) was increased in both soleus and EDL
myoblasts and reached about 65 to 70% at day 14 (Figures
6(a) and 6(c)). In anti-TGFβ1 antibody-treated cultures,
fusion of soleus myoblasts began earlier than in EDL cell
cultures, and the sizes of myotubes was more important
(Figures 6(b) and 6(d)).
Treatments of myoblasts with anti-TβRI antibody also
increased cell growth, but this increase was delayed by about
2 days compared to anti-TGFβ1 antibody treatment. Anti-
TβRIprolongedcellgrowthinbothsoleusandEDLmyoblast
cultures after day 10 following plating. Interestingly, anti-
TβRI accelerated myoblast fusion and increased the size of
myotubes even more eﬃciently than anti-TGFβ1( Figure 6).
Taken together, these results have shown that neutral-
ization of TGFβ1 activity or signalling through TGFβRI
impairment induced an increase in both proliferation and
fusion of myoblasts. Since the eﬀects of neutralization of
TGFβ activity on proliferation were kinetically diﬀerent in
soleus and EDL myoblasts cultures, this suggested also that
these cultures diﬀered in the pattern of expression of TGFβ1
in the course of diﬀerentiation.
3.5. Patterns of TGFβ1a n dT βRI Protein Expression during
In Vitro Diﬀerentiation of Soleus and EDL Derived Myoblasts.
Immunoblot analyses of TGFβ1 protein content were per-
formed from day 4 of culture in both soleus and EDL derived
myoblasts. The amount of TGFβ1 found at day 4 was taken
as reference (100%). In untreated (control) soleus myoblast
cultures (Figure 7(a)), the level of TGFβ1 protein in cellular
extracts increased to peak at day 10 after plating. In contrast,
in untreated EDL myoblast cultures TGFβ1 protein level
slightly decreased at day 8 compared to day 4, and then it
increased to reach a level about 160% of the day 4 level at day
14 of culture. Treatments with anti-TGFβ1 antibody seemed
to attenuate the variations of TGFβ1 amounts in the course
of diﬀerentiation, in both soleus and EDL myoblast cultures
during (Figure 7(a)).
T h ep a t t e r n so fT βR1 expression in soleus or EDL
c o n t r o lm y o b l a s tc u l t u r e sa l s od i ﬀered slightly (Figure 7(b)).
Whereas it did not change markedly during the 2 weeks of
culturing in control EDL cells, it increased slightly at day 14
in control soleus cell cultures. Treatment of myoblasts with
anti-TβRI antibody resulted in modiﬁcation of TβRI protein
level that dropped of about 30% at days 8 and 10 in soleus
cultures before increasing again. In EDL treated cultures, the
TβRI receptor level dropped at day 12 after plating, thus 4
days later than in soleus cell cultures.
These results have shown that myoblasts from soleus
and EDL muscles express TGFβ1 in vitro and display a
diﬀerential pattern of TGFβ1a n dT βRI protein expressions
when diﬀerentiating under identical cell culture conditions.
Changes in patterns of these proteins were all delayed by
about 2 to 4 days in EDL cultures compared to soleus
cultures.
3.6. The GAG Pattern Change during Soleus and EDL Muscle
Regeneration. GAGs are known to contribute to changes in
cell behavior by modifying the storage and availability of
bioactive molecules such as TGFβ. Thus the pattern of GAGs
at the beginning of regenerating soleus and EDL muscle
was established (Figure 8). In both muscles, sulphated GAG
contentincreasedcomparedtointactmusclesduringtheﬁrst
two weeks of the repair process. Whereas it reached a plateau
at day 7 after crush in EDL muscle, it increased continuously
in soleus regenerating muscle up to day 14. Treatment of
muscles with the anti-TGFβ1 antibody highly reduced the
a m o u n t so fG A G si nb o t hm u s c l e sf r o md a y5a f t e rc r u s h ,
especially in EDL. When crushed muscles were injected with
anti-TβRI antibody, GAG amounts in both muscles were
reducedalmostaseﬃcientlyasinthepresenceofanti-TGFβ1
(Figure 8). Thus a prolonged presence of TGFβ1i nm u s c l e
was associated with sustained GAG production, especially
in soleus muscle. This is in support of the hypothesis
that TGFβ1 activity alters GAG amount during muscle
regeneration as in number of other studies.
Skeletal muscles are composed of many diﬀerent cell
species, including inﬂammatory cells, each of them diversely
contributing to the production of GAGs. It was therefore
of interest to analyze the GAGs produced by the cells
responsible for muscle repair, that is, myoblasts and to
examine the eﬀect of TGFβ1 neutralization on these GAGs.
3.7. Changes in GAG Pattern during Diﬀerentiation of Soleus
and EDL Derived Myoblasts. The pattern of total GAG
content at cellular level slightly diﬀered in Soleus and EDL
derived myoblasts. In soleus myoblasts, the produced GAGs
increased from day 4 to peak when myotubes were formed
at day 8 and reached 3.5μgo fG A G / μg DNA then, they
decreased slightly (Figure 9(a)). The GAG peak in EDL
derived myoblasts occurred 2 days later than in soleusInternational Journal of Cell Biology 9
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Figure 6:Growth and diﬀer entiationo fso leusandEDLderi v edm y o b lasts.Eﬀectsofanti-TGFβ1andanti-TβRIantibody treatments.Untreated
myoblasts (control) and myoblasts treated at day 4 after plating (arrow) with either anti-TGFβ1 or anti-TβRI antibody were cultured as
described above. In the cultures of (a) soleus and (c) EDL derived myoblasts, cellular growth (shown as curves) was measured by counting
the cells after trypsin dissociation. Index of fusion (shown as bars) was expressed as the percentage of nuclei found in myotubes compared to
the total number of nuclei. Distributions of myotubes (as % of total myotubes) found in (b) soleus and (d) EDL derived myoblast cultures
according to their size, depending on the number of nuclei they contained. Counting was performed at the indicated days after plating on
cultures stained with May-Gr¨ unwald-Giemsa. Values are mean ± SE of three independent cultures.
cells and was at its maximum at day 10 when it reached
2.5μgG A G / μgD N A( Figure 9(a)). In fact, GAGs produced
were almost exclusively found in culture medium when
myoblasts proliferate (day 4). GAGs in culture medium then
diminished when cells diﬀerentiated (Figure 9(b)), more
drastically in the case of soleus cell culture. The amount
of HS species proportionally increased when cells of both
types achieved their diﬀerentiation, especially in soleus cell
cultures (Figure 9(c)).
Treatment of cells with anti-TGFβ1 altered the total GAG
content. In both types of myoblasts, it induced a sustained
level of total GAGs at the cellular level between days 10 and
14 of culture in diﬀerentiating cells when GAGs diminished
in controls. At the same time, anti-TGFβ1 highly reduced the
amount of GAGs found in culture medium (Figure 9(b)).
Anti-TβRI had similar eﬀects than anti-TGFβ1o nG A G
distribution between cells and medium (not shown). The
treatment of cells with anti-TGFβ1 further increased the
proportion of HS compared to controls in both cultures
(Figure 9(c)).
These results have shown that soleus and EDL derived
myoblasts synthesize GAGs that accumulate at the cellular
level when myoblasts fuse into myotubes. This accumulation
took place earlier in soleus than in EDL muscle cell culturesInternational Journal of Cell Biology 11
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cultures. Representative Immunoblots of (a) TGFβ1o r( b )T βRI from cultures of myoblasts derived from soleus and EDL muscles treated
with anti-TGFβ1a n da n t i - T βRI, respectively. Band densities of membranes were scanned. Results are given as bars (white for control and
gray for treated cultures) as a percentage of the density is found at day 4 in each condition. Each experiment was performed 3 times and
the results were expressed as mean ± SE. Control of loading with α-tubulin content in the immunoblot was routinely checked and did not
display signiﬁcant variability upon samples (not shown).12 International Journal of Cell Biology
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Figure 8: Sulphated GAGs content during soleus and EDL muscle regeneration. Total sulphated GAGs were measured using a method based on
dimethylmethylene blue coprecipitation with GAGs (see Materials and Methods Section) in extracts from regenerating control treated with
the indicated antibodies. Results are expressed as μg of GAG per mg of muscle fresh weight ± SE. Results are means from 3 animals repeated
3 times.
but occurred before the peak of TGFβ1i nb o t hm u s c l e s .T h e
antibodies that impaired TGFβ1 action accelerated myotube
formation. It also accelerated the accumulation of GAGs
at cellular level where the augmentation of HS species was
emphasized.
4. Discussion
Slow and fast twitch muscles, soleus, and EDL, respectively,
displayed diﬀerential aspects in the course of their regen-
eration after crush. As previously observed [14], whereas
EDL muscle regenerates properly, the soleus muscle displays
ﬁbrosis. The hypothesis that was presently explored was
that the diﬀerential regeneration ability of the fast and slow
muscles was associated to diﬀerential expressions of TGFβ1
in these muscles and in myoblasts derived from them.
The ﬁrst observation of this study was indeed that soleus
and EDL regenerating muscles displayed diﬀerent patterns
of TGFβ1 protein amounts as shown by immunoblot and
ELISA techniques. After an initial rise of TGFβ1a td a y1
aftercrush,thesoleusshowedasustainedlevelofthisprotein
over the 14 days after injury, but the amount of TGFβ1
found in EDL diminished at day 7. Immunoneutralization
of TGFβ1 action by using antibodies improved muscle
regeneration as shown by histological analysis. Correlatively,
anti-TGFβ1 treatment also anticipated a drop in the level
of this cytokine detected by immunoblotting, especially in
soleus regenerating muscles.
In many studies, TGFβ1a p p e a r sa sak e yc o m p o n e n t
that regulates a ﬁbrotic loop in muscle cells. In physiolog-
ical condition, it is commonly admitted that synthesis of
extracellular matrix molecules such as ﬁbronectin increases
during repair of tissue but decreases with the formation
of normal parenchyma. In our crush induced regeneration
model, EDL muscle which regenerates correctly, displayed
such a transient increase in TGFβ1 and ﬁbronectin. That was
not the case in regenerating soleus muscle where sustained
TGFβ1 and ﬁbronectin protein levels were correlated to a
poor qualityofregeneration. Liatal.have shownthatTGFβ1
triggers a transformation of myoblasts to ﬁbroblasts [23].
In addition, Brandan’s group have recently shown that PG
such as decorin and biglycan, which are known to regulate
TGFβ1 bioavailability, might originate at least partially from
ﬁbroblasts in vivo [49]. The improvement of the quality of
regenerated soleus muscles observed here in the presence of
anti-TGFβ1 might come from the fact that this loop was
minimized by treatment with the antibodies that impaired
TGFβ1e ﬀect.
The possibility that diﬀerentiating myoblasts in regen-
erating muscle might participate to the TGFβ1p r o d u c t i o n
had to be evaluated. To our knowledge, the production of
TGFβ1 by myoblasts isolated from soleus and EDL muscles
and grown in primary cultures has never been established. It
has been shown here that both cultures expressed TGFβ1b u t
the patterns of TGFβ1 expression diﬀered between the two
types of cultures. When TGFβ1 protein increased in soleus
cell cultures at day 10, it increased later (days 12–14) in
EDL cell cultures. In addition, myoblasts derived from these
muscles diﬀer in proliferating and diﬀerentiating properties,
thus corroborating previous ﬁndings [16]. It was presently
shown that in soleus cell cultures some myoblasts fused into
myotubesearlierthaninEDLcultures,whileothermyoblasts
remained proliferating a longer time than in EDL cultures.
Conﬂicting reports have been made on the role of TGFβ
in skeletal myoblast diﬀerentiation and in vivo myogenesis
[51]. Although many cells respond equally to diﬀerent
isoforms, it has been shown that TGFβ1 isoform totally
inhibits the terminal diﬀerentiation of the Sol 8 cell line
[52]. In the present study it was seen that TGFβ1p r o d u c e d
by cells did not prevent myoblast to fuse, whatever was itsInternational Journal of Cell Biology 13
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Figure 9: Sulphated GAG levels produced by diﬀerentiating myoblasts isolated from soleus and EDL muscles. Untreated myoblasts (control)
or myoblast treated at day 4 with anti-TGFβ1 antibody were cultured as described in Materials and Methods. (a) Total sulphated GAGs at
cellular level at the indicated days of culture. Data are mean ± SE from 3 determinations. (b) Sulphated GAG levels in conditioned medium
of soleus and EDL derived myoblast cultures. R e s u l t sw e r ee x p r e s s e da sn go fG A Gp r o d u c e dp e rc e l l± SE as a result of 3 determinations.
(c) Analysis of GAG species in EDL and Soleus derived myoblasts. HS, expressed as % of total GAG, was determined after a chondro¨ ıtinase
ABC treatment of the total GAG samples. Two determinations, that did not diﬀer by more than 10%, were used in this experiment.14 International Journal of Cell Biology
amount. However, although cell treatment with neutralizing
antibodies did not alter extensively the apparent amount of
TGFβ1 protein detected by immuno electrophoresis, it has
an important eﬀect on cell behavior. It seemed to induce an
appropriate state in cells that triggers them to fuse more pre-
cociously and intensively. The anti-TβRI antibody was even
more eﬃcient than the anti-TGFβ1i nt r i g g e r i n gm y o b l a s t
fusion. The presence of anti-TβRI antibody reduced for
several days, in both cultures, the amount of receptor,
suggestive of an autocrine loop between TGFβ1 and its
receptor. Precocious fusions observed herein treated cultures
could not be due to an increasing cell density that would
enhance the probability of fusion between neighbouring
myoblasts. In fact, at similarly low cellular densities, some
cultures presented numerous myotubes and others not.
Rather, these precocious fusions reﬂected intrinsic cellular
properties. As suggested by a study of Brandan’s group [53],
the increase in fusion associated to TGFβ1i m p a i r m e n tb ya n
appropriate antibody could be linked to an enhanced ability
of myoblasts to migrate.
Other factors might be involved in regulating the
cytokine activity. TGFβ family members are known to have
aﬃnity to proteoglycans. Most of the studies concerning the
role of proteoglycans on the regulation of TGFβ activity
have focused on the expression of their core protein com-
ponents. But a growing body of evidence has attributed
to sulphated glycosaminoglycans, a major importance in
regulating growth factor, cytokine, and chemiokine eﬀects
including TGFβ1. In the present study, the amount of
sulphated GAGs were increased in regenerating muscles
within the ﬁrst 2 weeks post-injury, especially in the soleus.
These GAGs might contribute to control TGFβ1a c t i v i t y .
Part of these GAGs were produced by activated satellite cells.
It is shown here that soleus and EDL derived myoblasts
produced increasing amounts of GAGs in vitro when cells
began to fuse. At the same time, the amount of GAGs in
the culture medium decreased. The peak of GAGs occurred
two days earlier in soleus myoblast cultures compared to
EDL myoblast cultures. This ﬁnding could be correlated with
the observation that soleus myoblasts fused earlier than EDL
myoblasts.ItmustbeemphasizedthatthemaximumofGAG
production at cellular level occurred before the maximum
of TGFβ1 protein in both culture types. These GAGs might
participate to the control of TGFβ1 signaling.
We previously have shown that an increasing amount
of GAGs, especially of the HS species, could be associated
to diﬀerentiating myoblasts using the C2.7 myoblast cell
line (Barbosa et al. 2005). An increased HS production by
diﬀerentiating soleus and EDL myoblasts was also observed
here.ItwasalsoshownthattheattenuationofTGFβ1activity
by using antibodies increased the amount of GAGs produced
by myoblasts at the cellular level and accelerated the shift
of GAG composition from CS to HS species. As it has been
shown that DS/CS moiety of some proteoglycans sequesters
TGFβ [54] and that its biological activity could be negatively
regulated by HS [55], it can be conceivable that GAGs,
principally of HS species synthesized by diﬀerentiating cells,
would ﬁnally diminish the action of this growth factor at
cellular level. The presence of antibodies would amplify this
eﬀect by favoring HS species accumulation. Such a virtuous
loop has been suggested in a study where epithelial cells
were used. In these cells, deﬁciency or enzymatic removal of
HS at the cellular surface attenuates degradation of TGFβ1
and increases TGFβ1 signaling [55]. However, since in vivo
in the presence of the antibodies, total amount of GAGs
measured in muscles was reduced compared to untreated
muscles in contrast with what was observed in vitro at
myoblastlevel.Thus,theparticipationofmyoblastsinvivoin
the production of GAGs might contribute to a minor degree
comparedtotheothercells,includinginﬂammatorycellsand
endothelial cells that compose the muscular tissue, without
forgetting ﬁbroblasts as recently underscore by Brandan’s
group [56].
The present study indicated that the control of TGFβ1
activity is necessary to improve regeneration of injured
muscle and myoblast diﬀerentiation, and that this eﬀect is in
partrelatedtoGAGcompositionofmusclecellenvironment.
The next steps would be to decipher the sequence of GAGs
produced in vivo in relation to interacting bioactive proteins
including TGFβ1 in regenerating muscles and to determine
their spatial distribution. Routine GAG sequencing tech-
niques,aswellastoolsforanalyzinglocalizationofsequences
biologically relevant for muscle diﬀerentiation, remain to be
available. Nevertheless, the present study supports the idea
that antagonizing TGFβ1action with neutralizing antibody
could rescue accurate skeletal muscle regeneration in part by
acting at the myoblast level through an alteration of GAG
environment.
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